


Is the Biosimilars Pathway Working for Patients?

JUST LOOK AT THE NUMBERS

In the **10 YEARS**

Since Congress established the biosimilars pathway



26

Biosimilars approved



5 Diseases
With biosimilar treatment options



Oncology



Hematology



Gastroenterology



Rheumatology



Dermatology



9

Biosimilars on the market

1,000+

Biosimilars in the pipeline¹



\$160

Billion Projected Savings

Over 5 years to the health care system²



70%

Physicians Are Confident

In standards for biosimilar interchangeability³



bpc

BiologicsPrescribers
COLLABORATIVE

A PROJECT OF AfPA

1. American Pharmaceutical Review. March 2019.

2. The IQVIA Institute. Jan 2019.

3. Biologics Prescribers Collaborative. Sept 2018.